MCLVX
Price
$31.89
Change
+$0.28 (+0.89%)
Updated
Jun 2 closing price
Net Assets
804.36M
VIVIX
Price
$83.17
Change
+$0.71 (+0.86%)
Updated
Jun 2 closing price
Net Assets
237.83B
Interact to see
Advertisement

MCLVX vs VIVIX

Header iconMCLVX vs VIVIX Comparison
Open Charts MCLVX vs VIVIXBanner chart's image
MCLVX vs VIVIX Comparison Chart in %
View a ticker or compare two or three
VS
MCLVX vs. VIVIX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCLVX is a Hold and VIVIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 238B vs. MCLVX (804M). VIVIX pays higher dividends than MCLVX: VIVIX (1.87) vs MCLVX (0.43). MCLVX was incepted earlier than VIVIX: MCLVX (26 years) vs VIVIX (28 years). MCLVX (1.75) is less costly to investors than VIVIX (0.03). MCLVX is a more actively managed with annual turnover of: 120.00 vs. VIVIX (8.00). MCLVX has a lower initial minimum investment than VIVIX: MCLVX (1000) vs VIVIX (5000000). VIVIX annual gain was more profitable for investors over the last year : 23.24 vs. MCLVX (19.38). VIVIX return over 5 years is better than : 50.71 vs. MCLVX (2.80).
MCLVXVIVIXMCLVX / VIVIX
Total Expense Ratio1.540.035,133%
Annual Report Gross Expense Ratio1.750.035,833%
Fund Existence26 years28 years-
Gain YTD14.23910.670133%
Front LoadN/AN/A-
Min. Initial Investment100050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets804M238B0%
Annual Yield % from dividends0.431.8723%
Returns for 1 year19.3823.2483%
Returns for 3 years33.6853.1863%
Returns for 5 years2.8050.716%
Returns for 10 years63.23150.4242%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVAAX38.42N/A
N/A
JPMorgan Value Advantage A
PCVAX13.00N/A
N/A
Virtus NFJ Small-Cap Value A
RTSAX46.98N/A
N/A
Russell Inv Tax-Managed US Mid&Sm Cap A
MDOAX12.52N/A
N/A
Morgan Stanley Developing Opportunity A
ERHSX13.49N/A
N/A
Eaton Vance Worldwide Health Sci R